Biontech Se Sponsored Adr Stock News

Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen's Bavarian Nordic in a $225 million deal.

Investors appear to be concerned that Uncle Sam won't foot the bill for additional COVID-19 vaccine purchases.

The picture is improving for vaccine stocks. But there's still a lot of uncertainty.

The FDA advisory committee meeting on Apr 6 is likely to give an insight into how the regulatory agency feels about the need for additional boosters of COVID-19 vaccines.

The momentum from earlier this week continues.

BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $165, moving +0.66% from the previous trading session.

Pfizer and BioNTech asked U.S. regulators on Tuesday to authorize an additional booster dose of their COVID-19 vaccine for seniors.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech File For Authorization Of Second Booster Dose Of COVID-19 Vaccine Pfizer, Inc. (NYSE: PFE ) and BioNTech SE (NASDAQ: BNTX ) said they have submitted an application to the U.S. Food and Drug Administration for the emergency use authorization of an additional booster dose for adults, 65 years of age and older, who have received an initial booster of any of the authorized or approved COVID-19 vaccines. Earlier this month, a CDC study found that the duo''s COVID-19 vaccine becomes less effective after four months following vaccination. Pfizer shares were up 0.73% at $52.59 in premarket trading and BioNTech shares were advancing 3.58% to $150.23. Iovance Gets FDA Approval to Commence Study Of TIL Therapy to Treat Lung Cancer Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) said the FDA has allowed an investigational new drug application to proceed with its first genetically modified tumor-infiltrating lymphocyte (TIL) therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage 3 or 4 non-small cell lung cancer.

Pfizer Inc (NYSE:PFE) and partner BioNTech SE (NASDAQ:BNTX) filed an application with the U.S. Food and Drug Administration this morning to approve emergency use authorization for a second booster sho

Pfizer Inc (NYSE: PFE ) and BioNTech SE (NASDAQ: BNTX ) filed an application with the FDA seeking emergency use authorization for a second booster shot of their COVID-19 vaccine for people aged 65 and older. An analysis of data from over 1.1 million adults 60 years and older showed rates of confirmed infections were two times lower, and severe illness was four times lower in … Full story available on Benzinga.com

Pfizer (PFE) and BioNTech (BNTX) believe that for individuals to be adequately protected, additional booster doses of COVID vaccines are needed.

MAINZ, GERMANY, March 16, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2021 on Wed

Japan intends to acquire 145M doses of Moderna (MRNA), and Pfizer (PFE) and BioNTech''s (BNTX) COVID-19 vaccines, Reuters reported citing Kyodo news agency which cited a…

Pfizer and its German partner BioNTech on Tuesday requested emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a second COVID-19 booster dose for seniors. This would be the fourth dose to the regimen of the Pfizer-BioNTech (Pfizer) COVID-19 vaccines for those aged 65 and over. In the United States, the primary […]

Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.